Septin9 gene methylation in plasma for gastric cancer detection: a systematic review and meta-analysis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-06-01 Epub Date: 2026-06-12 DOI:10.1080/17520363.2026.2685066

Yiming Wang, Yuan Wang, Jiaqi Kang, Shan He, Ping Zhang

{"title":"Septin9 gene methylation in plasma for gastric cancer detection: a systematic review and meta-analysis.","authors":"Yiming Wang, Yuan Wang, Jiaqi Kang, Shan He, Ping Zhang","doi":"10.1080/17520363.2026.2685066","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the plasma-based methylated Septin9 (mSEPT9) diagnostic accuracy for gastric cancer (GC) and analyze its performance across different subgroups.Methods: Through comprehensive computer searching, we systematically collected clinical trials on the diagnostic efficacy of plasma mSEPT9 in GC. The search scope covered PubMed, Web of Science, the Cochrane Library, Embase, CNKI, WanFang Data and VIP databases from their establishments to 31 August 2025. Study quality was rigorously assessed with the assistance of Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Meta-analysis via Stata 17.0 and Meta-Disc 1.4 was performed.Results: This study included 9 articles containing 10 studies, encompassing 3,120 participants. Meta-analysis revealed a pooled sensitivity of 0.40 (95%CI: 0.34-0.47), specificity of 0.94 (95%CI: 0.91-0.96), diagnostic odds ratio of 11.10 (95%CI: 6.42-19.18), area under the curve of 0.78 (95%CI: 0.74-0.82). Meta-regression identified sample size and positive criteria algorithm as potential contributors to heterogeneity in sensitivity, although the associations were only of borderline statistical significance. Other covariables were not significantly associated with heterogeneity.Conclusion: Plasma mSEPT9 demonstrated high specificity and relatively low sensitivity in GC. The assay may be unsuitable for general population screening but showed promise as an adjunctive marker in high-risk patients. Heterogeneity and geographical concentration may influence the assessment of mSEPT9.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251140125.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"531-542"},"PeriodicalIF":2.1000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432830/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2685066","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the plasma-based methylated Septin9 (mSEPT9) diagnostic accuracy for gastric cancer (GC) and analyze its performance across different subgroups.

Methods: Through comprehensive computer searching, we systematically collected clinical trials on the diagnostic efficacy of plasma mSEPT9 in GC. The search scope covered PubMed, Web of Science, the Cochrane Library, Embase, CNKI, WanFang Data and VIP databases from their establishments to 31 August 2025. Study quality was rigorously assessed with the assistance of Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Meta-analysis via Stata 17.0 and Meta-Disc 1.4 was performed.

Results: This study included 9 articles containing 10 studies, encompassing 3,120 participants. Meta-analysis revealed a pooled sensitivity of 0.40 (95%CI: 0.34-0.47), specificity of 0.94 (95%CI: 0.91-0.96), diagnostic odds ratio of 11.10 (95%CI: 6.42-19.18), area under the curve of 0.78 (95%CI: 0.74-0.82). Meta-regression identified sample size and positive criteria algorithm as potential contributors to heterogeneity in sensitivity, although the associations were only of borderline statistical significance. Other covariables were not significantly associated with heterogeneity.

Conclusion: Plasma mSEPT9 demonstrated high specificity and relatively low sensitivity in GC. The assay may be unsuitable for general population screening but showed promise as an adjunctive marker in high-risk patients. Heterogeneity and geographical concentration may influence the assessment of mSEPT9.

Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251140125.

查看原文本刊更多论文

血浆Septin9基因甲基化检测胃癌：系统综述和荟萃分析。

目的：评价血浆甲基化sept9 （mSEPT9）对胃癌（GC）的诊断准确性，并分析其在不同亚组中的表现。方法：通过计算机综合检索，系统收集血浆mSEPT9对胃癌诊断效果的临床试验。检索范围涵盖PubMed、Web of Science、Cochrane Library、Embase、CNKI、万方数据和VIP数据库，检索时间截止至2025年8月31日。在诊断准确性研究质量评估-2 （QUADAS-2）的帮助下严格评估研究质量。采用Stata 17.0和Meta-Disc 1.4进行meta分析。结果：本研究纳入9篇文章，包含10项研究，涉及3120名受试者。荟萃分析显示，合并敏感性为0.40 (95%CI: 0.34 ~ 0.47)，特异性为0.94 (95%CI: 0.91 ~ 0.96)，诊断优势比为11.10 (95%CI: 6.42 ~ 19.18)，曲线下面积为0.78 （95%CI: 0.74 ~ 0.82）。meta回归确定样本量和阳性标准算法是敏感性异质性的潜在因素，尽管相关性仅具有临界统计学意义。其他协变量与异质性无显著相关。结论：血浆mSEPT9在GC中具有较高的特异性和较低的敏感性。该检测可能不适合用于一般人群筛查，但作为高风险患者的辅助标记物显示出了希望。异质性和地理集中可能影响mSEPT9的评估。协议注册：www.crd.york.ac.uk/prospero标识为CRD420251140125。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.